News & Topics
News&Topics

2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008 / 2007 / 2006 / 2005

2018.12.12
Analyst Report[Strategy update](EDISON)
2018.12.07
Analyst Report[Full report] (Shared Research)
2018.12.04
Onconova Presents Results from Phase 2 Trial of Oral Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2018 Meeting
2018.11.30
Clinical Trial Begins for TREAKISYM Liquid Formulation(Rapid Infusion Injection Formulation)
2018.11.09
Analyst Report[Update report]: Shared Research updates the report
2018.11.08
Analyst Report[Follow-up Report] (Fair Research)
2018.11.06
Onconova Announces Presentation on Rigosertib in Myelodysplastic Syndromes at 2018 ASH Annual Meeting & Exposition
2018.10.17
Onconova Announces Issuance of a New U.S. Patent for Rigosertib
2018.10.16
SymBio Begins Preparation for Own Sales Organization for the Anti-Cancer Agent TREAKISYM
2018.10.01
Completion and Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2018.10.01
Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2018.09.27
SymBio files Partial Change Application for use of TREAKISYM as a Pretreatment to Regenerative Medical Products
2018.09.25
Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2018.09.05
Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2018.09.03
Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2018.08.30
Analyst Report[Full report] (Shared Research)
2018.08.29
Launch of New Anti-CD20 Antibodies that can be used in combination with the anti-cancer agent TREAKISYM
2018.08.29
Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2018.08.21
Analyst Report[Basic Report] (Fair Research)
2018.08.07
Analyst Report[Update report]: Shared Research updates the report
2018.08.07
Notice Concerning Non-operating Expenses
2018.08.07
Summary of Financial Results for the First Half of Fiscal Year Ending December 31, 2018 [Japanese GAAP] (Non-consolidated)
2018.08.01
Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2018.07.30
Revised Medical Practice Guidelines 2018 for Healthcare Professionals
2018.07.25
Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2018.07.09
Eagle Announces New Patent Issued for Bendamustine Hydrochloride Injection in the U.S.
2018.07.04
Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2018.07.02
TREAKISYM Receives Approval for Combined Use with Anti-CD20 Antibodies
2018.07.02
Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2018.06.18
Eagle Announces U.S. Court Decision Granting Orphan Drug Exclusivity for Bendamustine Hydrochloride Injection in the U.S.
2018.06.06
Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2018.06.01
Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2018.05.28
Analyst Report[Full report]: Shared Research updates the report
2018.05.28
First Patient Enrolled in Phase 1 Clinical Trial for Oral TREAKISYM for Progressive Solid Tumors
2018.05.18
TREAKISYM Sales Forecast for FY2018
2018.05.10
Analyst Report[Update report]: Shared Research updates the report
2018.05.10
Summary of Financial Results for the First Quarter of Fiscal Year Ending December 31, 2018 [Japanese GAAP] (Non-consolidated)
2018.05.10
Notice Concerning Non-operating Expenses
2018.05.10
Initiation of Collaborative Research with Keio University on TREAKISYM for Systemic Lupus Erythematosus
2018.05.01
Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2018.04.26
(Correction Notice of Press Release) Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
2018.04.26
(Correction Notice of Press Release) Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
2018.04.26
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
2018.04.26
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
2018.04.25
Completion of Payment for Subscription for the 45th through 47th Stock Acquisition Rights (with Exercise Price Revision Clauses)
2018.04.18
TREAKISYM Achieves 50% Market Share for 1st Line Low Grade Non-Hodgkin Lymphoma
2018.04.09
Analyst Report[Update report]: Shared Research updates the report
2018.04.09
Notice of the Issuance of the 45th through 47th Stock Acquisition Rights with Exercise Price Revision Clauses (Commit Issue Program) and Conclusion of an Unsecured Loan Facility Agreement
2018.03.30
Notice of Shareholder Voting Results for the 13th Ordinary General Meeting of Shareholders
2018.03.29
Notice Concerning the Issuance of Stock Acquisition Rights to Directors
2018.03.29
Notice Concerning the Issuance of Stock Acquisition Rights to Employees
2018.03.29
Notice of Board of Director, Audit & Supervisory Board, and Corporate Officer Appointments
2018.03.27
Analyst Report[Full report]: Shared Research updates the report
2018.03.13
Information on Shareholders' Meeting: Updated the Page
2018.03.06
Notice concerning Nominations for the Board of Directors/the Audit & Supervisory Board/and Substitute Member for the Audit & Supervisory Board
2018.02.19
Analyst Report[Basic Report]: Fair Research updates the report
2018.02.09
Termination of the Development of the Patient-controlled Pain Management Drug "SyB P-1501"
2018.02.07
Analyst Report[Update report]: Shared Research updates the report
2018.02.07
SymBio's Mid-Range Plan: FY2018 to FY2021
2018.02.07
Summary of Financial Statements for the Fiscal Year Ended December 31, 2017 [Japanese GAAP] (Non-consolidated)
2018.02.07
Notice Concerning Non-Operating Income
2018.01.22
Initiation of Phase 1 Clinical Trial for Oral TREAKISYM in Progressive Solid Tumors
2018.01.18
Onconova Announces Plans for the Global Randomized Phase 3 Trial of IV Rigosertib after Promising Interim Analysis